Chugai Pharmaceutical Co., Ltd. researches, develops, manufactures, sells, imports and exports pharmaceuticals in Japan and internationally, including oncology products such as Alecensa, Avastin, Tecentriq and Polivy, as well as Actemra, Hemlibra, Evrysdi, Enspryng, PiaSky, Vabysmo, Mircera, CellCept and Tamiflu. A subsidiary of Roche Holding AG, it collaborates with Phylo, Inc. on an agentic AI platform for drug discovery.